kynurenic acid has been researched along with Migraine Disorders in 11 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In recent years, migraine research focused on tryptophan, which is metabolized via two main pathways, the serotonin and kynurenine pathways, both of which produce neuroactive molecules that influence pain processing and stress response by disturbing neural and brain hypersensitivity and by interacting with molecules that control vascular and inflammatory actions." | 5.22 | Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms. ( Körtési, T; Spekker, E; Vécsei, L, 2022) |
| " Neurogenic inflammation is presumed to be an important factor in migraine pathophysiology, mediated by the activation of primary neurons, leading to the release of various pro-inflammatory neuropeptides and neurotransmitters such as Calcitonin Gene-Related Peptide (CGRP), substance P (SP), and vasoactive intestinal peptide (VIP)." | 4.95 | Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects. ( Edvinsson, L; Fulop, F; Lukacs, M; Tajti, J; Toldi, J; Vecsei, L, 2017) |
| "Migraine is one of the most disabling neurological conditions and associated with high socio-economic costs." | 2.61 | The Therapeutic Impact of New Migraine Discoveries. ( Edvinsson, L; Fülöp, F; Lukács, M; Tajti, J; Toldi, J; Vécsei, L, 2019) |
| "Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed." | 2.52 | Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design. ( Csati, A; Fulop, F; Majlath, Z; Szok, D; Tajti, J; Toldi, J; Vecsei, L, 2015) |
| "The primary cause and the origin of migraine attacks are enigmatic." | 2.47 | Migraine is a neuronal disease. ( Bohár, Z; Fejes, A; Kuris, A; Párdutz, A; Tajti, J; Toldi, J; Tuka, B; Vámos, E; Vécsei, L, 2011) |
| "Migraine is a debilitating neurological disorder where trigeminovascular activation plays a key role." | 1.46 | Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). ( Edvinsson, L; Fülöp, F; Lukács, M; Tajti, J; Toldi, J; Vécsei, L; Warfvinge, K, 2017) |
| "Results KYNA-A1 abolished NTG-induced hyperalgesia in both pain models; NTG alone or associated to formalin injection induced an increased mRNA expression of CGRP, nNOS and cytokines in the trigeminal ganglia and central areas, which was reduced by KYNA-A1." | 1.46 | Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. ( Blandini, F; Demartini, C; Fülöp, F; Greco, R; Nappi, G; Pampalone, S; Redavide, E; Sandrini, G; Tassorelli, C; Toldi, J; Vécsei, L; Zanaboni, AM, 2017) |
| "The complex pathophysiology of migraine is not yet clearly understood; therefore, experimental models are essential for the investigation of the processes related to migraine headache, which include cortical spreading depression (CSD) and NO donor-induced neurovascular changes." | 1.46 | Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues. ( Knapp, L; Kocsis, K; Szita, B; Toldi, J; Vécsei, L, 2017) |
| "These findings suggest that in migraine KYN is unidirectionally metabolized into ANA at expenses of KYNA and 3-HK." | 1.42 | Altered kynurenine pathway metabolites in serum of chronic migraine patients. ( Capi, M; Curto, M; Fazio, F; Giamberardino, MA; Lionetto, L; Martelletti, P; Negro, A; Nicoletti, F; Simmaco, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Körtési, T | 2 |
| Spekker, E | 2 |
| Vécsei, L | 10 |
| Lukács, M | 3 |
| Warfvinge, K | 1 |
| Tajti, J | 6 |
| Fülöp, F | 6 |
| Toldi, J | 8 |
| Edvinsson, L | 3 |
| Oláh, G | 1 |
| Herédi, J | 1 |
| Menyhárt, A | 1 |
| Czinege, Z | 1 |
| Nagy, D | 1 |
| Fuzik, J | 1 |
| Kocsis, K | 2 |
| Knapp, L | 2 |
| Krucsó, E | 1 |
| Gellért, L | 1 |
| Kis, Z | 1 |
| Farkas, T | 1 |
| Párdutz, A | 2 |
| Majlath, Z | 1 |
| Szok, D | 1 |
| Csati, A | 1 |
| Curto, M | 1 |
| Lionetto, L | 1 |
| Negro, A | 1 |
| Capi, M | 1 |
| Fazio, F | 1 |
| Giamberardino, MA | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Martelletti, P | 1 |
| Greco, R | 1 |
| Demartini, C | 1 |
| Zanaboni, AM | 1 |
| Redavide, E | 1 |
| Pampalone, S | 1 |
| Blandini, F | 1 |
| Nappi, G | 1 |
| Sandrini, G | 1 |
| Tassorelli, C | 1 |
| Szita, B | 1 |
| Vámos, E | 2 |
| Tuka, B | 1 |
| Kuris, A | 1 |
| Bohár, Z | 1 |
| Fejes, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploration of the Role of Tryptophan Metabolites in Pediatric Migraine[NCT05969990] | 200 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for kynurenic acid and Migraine Disorders
| Article | Year |
|---|---|
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.
Topics: Humans; Kynurenic Acid; Kynurenine; Metabolic Networks and Pathways; Migraine Disorders; Pain; Serot | 2022 |
Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects.
Topics: Animals; Calcitonin Gene-Related Peptide; Drug Discovery; Humans; Kynurenic Acid; Migraine Disorders | 2017 |
The Therapeutic Impact of New Migraine Discoveries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Cl | 2019 |
Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design.
Topics: Drug Design; Humans; Kynurenic Acid; Migraine Disorders; Molecular Structure; Neurodegenerative Dise | 2015 |
Migraine is a neuronal disease.
Topics: Animals; Brain Stem; Calcitonin Gene-Related Peptide; Cerebral Cortex; Cortical Spreading Depression | 2011 |
6 other studies available for kynurenic acid and Migraine Disorders
| Article | Year |
|---|---|
Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72).
Topics: Administration, Topical; Animals; Dura Mater; Freund's Adjuvant; Gene Expression Regulation; Glutami | 2017 |
Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability.
Topics: Animals; Blood-Brain Barrier; Cortical Spreading Depression; Dizocilpine Maleate; Electroencephalogr | 2013 |
Altered kynurenine pathway metabolites in serum of chronic migraine patients.
Topics: Adult; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; Male; Middle Aged; Migr | 2015 |
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms.
Topics: Animals; Excitatory Amino Acid Antagonists; Hyperalgesia; Kynurenic Acid; Male; Migraine Disorders; | 2017 |
Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.
Topics: Cortical Spreading Depression; Dose-Response Relationship, Drug; Humans; Injections, Intraperitoneal | 2017 |
Protective compounds in animal models of trigeminal activation and neurodegeneration.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combi | 2012 |